Published in Protein Sci on September 01, 1993
The pharmacophore of the human C5a anaphylatoxin. Protein Sci (1994) 0.88
Primary structure and functional characterization of rat C5a: an anaphylatoxin with unusually high potency. Protein Sci (1994) 0.83
Solution structure of a unique C5a semi-synthetic antagonist: implications in receptor binding. Protein Sci (1997) 0.81
Antagonistic peptides against human anaphylatoxin C5a. Immunology (1995) 0.78
Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. J Immunol (1987) 4.43
Anaphylatoxins: C3a and C5a. Adv Immunol (1978) 3.44
Structure and function of the anaphylatoxins. Springer Semin Immunopathol (1984) 2.07
Ability of activated complement components to induce lysosomal enzyme release from macrophages. Nature (1976) 1.85
Isolation of three separate anaphylatoxins from complement-activated human serum. Mol Cell Biochem (1981) 1.70
The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a. Crit Rev Immunol (1981) 1.51
Interleukin 3-dependent mediator release in basophils triggered by C5a. J Exp Med (1989) 1.48
Pulmonary injury induced by C3a and C5a anaphylatoxins. Am J Pathol (1980) 1.48
Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. Proc Natl Acad Sci U S A (1989) 1.26
Crystal structure analysis and molecular model of human C3a anaphylatoxin. Hoppe Seylers Z Physiol Chem (1980) 1.25
Complement-mediated release of histamine from human leukocytes. J Immunol (1975) 1.20
Comparison of the Fc receptors for IgE on human lymphocytes and monocytes. J Immunol (1982) 1.11
Biologic activity of synthetic analogues of C5a anaphylatoxin. J Immunol (1992) 1.07
Characterization of the human neutrophil response to sex pheromones from Streptococcus faecalis. Am J Pathol (1989) 1.05
High-level expression of a gene encoding the human complement factor C5a in Escherichia coli. Gene (1986) 1.01
Designing synthetic superagonists of C3a anaphylatoxin. Biochemistry (1991) 0.98
Model structure for the inflammatory protein C5a. Science (1985) 0.92
Evidence for a role of the amino-terminal region in the biological activity of the classical anaphylatoxin, porcine C5a des-Arg-74. J Biol Chem (1985) 0.91
Three-dimensional structure of porcine C5adesArg from 1H nuclear magnetic resonance data. Biochemistry (1990) 0.91
Human C5a anaphylatoxin: gene synthesis, expression, and recovery of biologically active material from Escherichia coli. Methods Enzymol (1988) 0.88
Human C5a-related synthetic peptides as neutrophil chemotactic factors. Biochem Biophys Res Commun (1979) 0.85
Construction and expression of a novel recombinant anaphylatoxin, C5a-N19, as a probe for the human C5a receptor. Biochemistry (1990) 0.84
Studies on heart anaphylaxis. V. Cross-desensitisation between antigen, anaphylatoxin, and compound 48-80 in the guinea-pig papillary muscle. Int Arch Allergy Appl Immunol (1972) 0.82
Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol (1978) 6.04
Anaphylatoxins: C3a and C5a. Adv Immunol (1978) 3.44
Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A (1978) 3.08
Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a. J Immunol (1976) 2.90
Determination of the tryptophan content of proteins by ion exchange chromatography of alkaline hydrolysates. J Biol Chem (1972) 2.72
Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med (1981) 2.63
Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology (1975) 2.62
The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol (1979) 2.58
Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a. J Biol Chem (1978) 2.32
Human anaphylatoxin (C3a) from the third component of complement. Primary structure. J Biol Chem (1975) 2.08
Structure and function of the anaphylatoxins. Springer Semin Immunopathol (1984) 2.07
Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9. Proc Natl Acad Sci U S A (1984) 2.01
Activation of complement components C3 and C5 by a cysteine proteinase (gingipain-1) from Porphyromonas (Bacteroides) gingivalis. J Biol Chem (1992) 1.96
Purification and partial characterization of human and porcine C3a anaphylatoxin. J Biol Chem (1975) 1.82
Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest (1996) 1.77
Isolation of three separate anaphylatoxins from complement-activated human serum. Mol Cell Biochem (1981) 1.70
Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment. J Immunol (2000) 1.57
A modified method for chemotaxis under agarose. J Immunol Methods (1979) 1.55
Heat-induced fragmentation of human alpha 2-macroglobulin. J Biol Chem (1979) 1.53
The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a. Crit Rev Immunol (1981) 1.51
Role of cell surface contact in the kinetics of superoxide production by granulocytes. J Clin Invest (1983) 1.48
Pulmonary injury induced by C3a and C5a anaphylatoxins. Am J Pathol (1980) 1.48
Endotoxin-induced shock in the rat. A role for C5a. Am J Pathol (1989) 1.44
Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. J Immunol (1983) 1.44
Human C5a and C5a analogs as probes of the neutrophil C5a receptor. Mol Immunol (1980) 1.41
Regulation of immune response by components of the complement cascade and their activated fragments. Springer Semin Immunopathol (1983) 1.41
Arachidonate metabolism by human polymorphonuclear leukocytes stimulated by N-formyl-Met-Leu-Phe or complement component C5a is independent of phospholipase activation. Proc Natl Acad Sci U S A (1983) 1.37
C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med (1995) 1.36
Neutrophil chemotactic factors promote leukocytosis. A common mechanism for cellular recruitment from bone marrow. J Immunol (1992) 1.36
C4a: the third anaphylatoxin of the human complement system. Proc Natl Acad Sci U S A (1979) 1.34
Induction of interleukin-8 synthesis from monocytes by human C5a anaphylatoxin. Am J Pathol (1994) 1.28
Limited degradation of the third component (C3) of human complement by human leukocyte elastase (HLE): partial characterization of C3 fragments. Biochemistry (1977) 1.26
Structural changes accompanying enzymatic activation of human Hageman factor. J Clin Invest (1974) 1.25
Biochemistry and biology of anaphylatoxins. Complement (1986) 1.25
Characterization of a C5a receptor on human polymorphonuclear leukocytes (PMN). J Immunol (1985) 1.23
Identification of classical anaphylatoxin as the des-Arg form of the C5a molecule: evidence of a modulator role for the oligosaccharide unit in human des-Arg74-C5a. Proc Natl Acad Sci U S A (1981) 1.23
Suppression of T lymphocyte functions by human C3 fragments. I. Inhibition of human T cell proliferative responses by a kallikrein cleavage fragment of human iC3b. J Immunol (1983) 1.22
Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids. Anal Biochem (1984) 1.21
Anti-C5a receptor antibodies. Characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted amino-terminal sequence of the human C5a receptor. J Immunol (1993) 1.21
Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release. J Clin Invest (1979) 1.20
C5a-induced hemodynamic and hematologic changes in the rabbit. Role of cyclooxygenase products and polymorphonuclear leukocytes. Am J Pathol (1987) 1.18
Anaphylatoxin from the fifth component of porcine complement. Purification and partial chemical characterization. J Biol Chem (1979) 1.17
C5a-mediated release of interleukin 6 by human monocytes. Clin Immunol Immunopathol (1990) 1.16
Synthetic peptides with the biological activities and specificity of human C3a anaphylatoxin. Proc Natl Acad Sci U S A (1977) 1.16
C5a-dependent up-regulation in vivo of lung vascular P-selectin. J Immunol (1997) 1.15
Proteolytic inactivation of the leukocyte C5a receptor by proteinases derived from Porphyromonas gingivalis. Infect Immun (1996) 1.15
Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury. Crit Care Med (1994) 1.14
Circular dichroism of C3a anaphylatoxin. Effects of pH, heat, guanidinium chloride, and mercaptoethanol on conformation and function. J Biol Chem (1975) 1.14
Microvascular effects of anaphylatoxins C3a and C5a. J Immunol (1985) 1.13
Anaphylactic actions of platelet-activating factor. Am J Pathol (1981) 1.12
Release of leukotrienes from guinea pig lung stimulated by C5ades Arg anaphylatoxin. J Immunol (1982) 1.10
Response of human neutrophils to C5a: a role for the oligosaccharide moiety of human C5ades Arg-74 but not of C5a in biologic activity. J Immunol (1981) 1.10
Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue. Am J Pathol (1983) 1.10
Quantitative comparisons of neutrophil chemotaxis in four animal species. Clin Immunol Immunopathol (1980) 1.09
Leukotriene C4 production by murine mast cells: evidence of a role for extracellular leukotriene A4. Proc Natl Acad Sci U S A (1985) 1.08
Peptidergic pathway in human skin and rat peritoneal mast cell activation. Immunopharmacology (1994) 1.08
The extraction of leukotrienes (LTC4, LTD4, and LTE4) from tissue fluids: the metabolism of these mediators during IgE-dependent hypersensitivity reactions in lung. Anal Biochem (1983) 1.08
The active site of C3a anaphylatoxin. J Biol Chem (1980) 1.07
Elucidation of a protease-sensitive site involved in the binding of calcium to C-reactive protein. Biochemistry (1989) 1.07
Inability of the C3a anaphylatoxin to promote cellular lysis. Nature (1980) 1.07
Biologic activity of synthetic analogues of C5a anaphylatoxin. J Immunol (1992) 1.07
Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol (1999) 1.06
The pancreas as a source of cardiovascular cell activating factors. Microcirculation (2000) 1.06
Characterization of the human neutrophil response to sex pheromones from Streptococcus faecalis. Am J Pathol (1989) 1.05
Conformational analysis of COOH-terminal segments of human C3a. Evidence of ordered conformation in an active 21-residue peptide. J Biol Chem (1984) 1.05
A mechanism of action for anaphylatoxin C3a stimulation of mast cells. J Immunol (1992) 1.04
Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg). J Immunol (1999) 1.03
C3a and C5a enhance granulocyte adhesion to endothelial and epithelial cell monolayers: epithelial and endothelial priming is required for C3a-induced eosinophil adhesion. Immunopharmacology (2000) 1.03
Anaphylatoxin-mediated regulation of the immune response. II. C5a-mediated enhancement of human humoral and T cell-mediated immune responses. J Immunol (1983) 1.02
Complete primary structure of human C4a anaphylatoxin. J Biol Chem (1981) 1.01
Identification and characterization of the effector region within human C5a responsible for stimulation of IL-6 synthesis. J Immunol (1992) 1.01
The primary structure of porcine C3a anaphylatoxin. J Immunol (1976) 1.01
Regulation of B cell functions by C3a and C3a(desArg): suppression of TNF-alpha, IL-6, and the polyclonal immune response. J Immunol (1997) 1.00
The molecular architecture of human complement component C6. J Biol Chem (1989) 1.00
Anaphylatoxin-mediated regulation of human and murine immune responses. Fed Proc (1984) 1.00
Complement factors and their receptors. Immunopharmacology (1997) 1.00
The activation of human complement component C5 by a fluid phase C5 convertase. J Biol Chem (1983) 1.00
Effect of C3a and C5a anaphylatoxins on guinea-pig isolated blood vessels. J Pharmacol Exp Ther (1984) 1.00
Psychopharmacological activity of anaphylatoxin C3a in rat hypothalamus. J Neuroimmunol (1983) 0.99
The extracellular neutral cysteine proteinase of Entamoeba histolytica degrades anaphylatoxins C3a and C5a. J Immunol (1995) 0.99
Anaphylatoxin generation in multisystem organ failure. J Trauma (1984) 0.98
Designing synthetic superagonists of C3a anaphylatoxin. Biochemistry (1991) 0.98
Multiple epithelial cell-derived factors enhance neutrophil survival. Regulation by glucocorticoids and tumor necrosis factor-alpha. Am J Respir Cell Mol Biol (1999) 0.97
Amino acid sequence of the anaphylatoxin from the fifth component of porcine complement. J Biol Chem (1980) 0.97
C3d-K, a kallikrein cleavage fragment of iC3b is a potent inhibitor of cellular proliferation. J Immunol (1984) 0.97
An amphiphilic structure of the ninth component of human complement. Evidence from analysis of fragments produced by alpha-thrombin. J Biol Chem (1982) 0.97
Oxidation of leukotrienes at the omega end: demonstration of a receptor for the 20-hydroxy derivative of leukotriene B4 on human neutrophils and implications for the analysis of leukotriene receptors. Proc Natl Acad Sci U S A (1984) 0.96
Plasma activation during splanchnic arterial occlusion shock. Shock (2000) 0.95
Anaphylatoxin binding and degradation by rat peritoneal mast cells. Mechanisms of degranulation and control. J Immunol (1990) 0.95
Effects of cardiopulmonary bypass on pulmonary leukostasis and complement activation. Arch Surg (1988) 0.95
Isolation and characterization of insoluble proteins of the synaptic plasma membrane. Arch Biochem Biophys (1968) 0.93
Demonstration of a specific C3a receptor on guinea pig platelets. J Immunol (1988) 0.93
Familial carboxypeptidase N deficiency. Ann Intern Med (1980) 0.93
Cleavage of human complement component C5 by cysteine proteinases from Porphyromonas (Bacteroides) gingivalis. Prior oxidation of C5 augments proteinase digestion of C5. Immunology (1996) 0.92
Circular dichroism studies of human factor H. A regulatory component of the complement system. Biochim Biophys Acta (1982) 0.92
Anaphylatoxin C5a modulation of an alpha-adrenergic receptor system in the rat hypothalamus. J Neuroimmunol (1985) 0.92
Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin Chem (1999) 0.92
The preparation and characterization of an active derivative of bovine pancreatic deoxyribonuclease A formed by selective cleavage with alpha-chymotrypsin. J Biol Chem (1973) 0.92